Región:
Todas las edicionesMetodologíaActualizado · septiembre de 2026
Investigación de agonistas duales GIP/GLP-1

Tirzepatide.
1 proveedor · US$2121

Agonista dual del receptor de GIP/GLP-1, aprobado por la FDA y la EMA como Mounjaro y Zepbound. La tirzepatida de viales de investigación es distinta y no aprobada, no fabricada ni revisada como esos medicamentos, ni apta para uso humano.

Clase con análogo aprobadoVial liofilizadoTambién conocido como:Mounjaro · Zepbound
Especificación del compuesto
Fórmula
C₂₂₅H₃₄₈N₄₈O₆₈
CAS
2023788-19-2
MW
4813 g/mol
Vida media
Aproximadamente 5 días (humano; información de prescripción de Mounjaro, sección 12.3)
Almacenamiento
Polvo liofilizado por debajo de −15 °C, bien cerrado y protegido de la luz; dejar que el vial sellado alcance temperatura ambiente antes de abrirlo. Viales reconstituidos a 2–8 °C.
Tamaños
10 mg, 15 mg
Qué es

El compuesto. Origen, investigación y realidad regulatoria.

Tirzepatide is a synthetic dual GIP/GLP-1 receptor agonist developed by Eli Lilly: a 39-amino-acid peptide engineered from the native GIP sequence with a fatty-diacid moiety for albumin binding. The FDA approved it as Mounjaro for type 2 diabetes on 13 May 2022 and as Zepbound for chronic weight management on 8 November 2023; Mounjaro is also authorised by the EMA.

The SURPASS trial programme characterised its dual-receptor mechanism and glucose-lowering action in adults with type 2 diabetes, including SURPASS-1 (Rosenstock et al., 2021) and a head-to-head comparison with semaglutide (Frías et al., 2021). The SURMOUNT programme (Jastreboff et al., 2022) studied its effect on body weight in adults with obesity or overweight through the same mechanism.

As Mounjaro and Zepbound, tirzepatide is prescription-only, manufactured and reviewed under FDA and EMA oversight, and its US prescribing information carries a boxed warning for thyroid C-cell tumours observed in rats. Research-use-only tirzepatide vials sold outside that supply chain are not those products and have not been reviewed for safety, effectiveness or quality. The FDA has warned of fraudulently compounded tirzepatide and has warned companies that illegally sold unapproved tirzepatide falsely labelled ‘for research purposes’.

Registro en vivo de proveedores · ordenado por precio

Cada proveedor. Mismo compuesto, ordenado ascendente.

TIRZEPATIDE · normalizado por precio
1 oferta · proveedores sin advertencia primero
01
QSC PeptidesSelecciónVID-QSC-PEPT · Kit de 10
15 mg
99%
HPLC · MS · Janoshik
En stock
7–14 días (internacional)
21 US$
Literatura representativa

Contexto de investigación. Trabajo reciente revisado por pares.

2021 · Lancet
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1)
2021 · N. Engl. J. Med.
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2)
citado por n = 1879DOI
2022 · N. Engl. J. Med.
Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)
citado por n = 2539DOI
Preguntas frecuentes

Lo que más se pregunta.

Is tirzepatide legal to buy?

Mounjaro and Zepbound are prescription-only medicines. Research-use-only tirzepatide vials are sold for laboratory research, not human use; RUO labelling does not make personal use or import legal everywhere.

How does research-vial tirzepatide differ from Mounjaro or Zepbound?

The approved pens are manufactured and reviewed under FDA/EMA oversight and carry a boxed thyroid-tumour warning based on reviewed safety data. Research vials come from an unreviewed supply chain with no verified purity or delivery controls.

What should a CoA show for tirzepatide?

HPLC purity, LC-MS mass confirmation matching C225H348N48O68 (MW ~4813), a lot number, an independent third-party lab name and a test date. The FDA has warned of fraudulently labelled compounded tirzepatide products.